Healthy Volunteers | Hypersensitivity Investigational New Drugs | Hypersensitivity Compound Related
Item
the volunteer has a known hypersensitivity to the study drug or to compounds chemically related;
boolean
C1708335 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C1706082 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
Liver diseases | Gastrointestinal Diseases | Condition Interferes with Drug absorption | Condition Interferes with Drug distribution | Condition Interferes with Drug elimination | Condition Interferes with Drug metabolism
Item
history or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism;
boolean
C0023895 (UMLS CUI [1])
C0017178 (UMLS CUI [2])
C0348080 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0678745 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0699903 (UMLS CUI [4,3])
C0348080 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0683141 (UMLS CUI [5,3])
C0348080 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0683140 (UMLS CUI [6,3])
Nervous system disorder | Endocrine System Diseases | Lung diseases | Hematological Disease | Immune System Diseases | Brain Diseases | Metabolic Diseases | Cardiovascular Diseases
Item
history of neurological, endocrine, pulmonary, hamatologic, immune, brain, metabolic or cardiovascular illness;
boolean
C0027765 (UMLS CUI [1])
C0014130 (UMLS CUI [2])
C0024115 (UMLS CUI [3])
C0018939 (UMLS CUI [4])
C0021053 (UMLS CUI [5])
C0006111 (UMLS CUI [6])
C0025517 (UMLS CUI [7])
C0007222 (UMLS CUI [8])
Hypotension | Hypertensive disease | Requirement Pharmacotherapy
Item
hypo or hypertension of any etiologic that needs pharmacologic treatment;
boolean
C0020649 (UMLS CUI [1])
C0020538 (UMLS CUI [2])
C1514873 (UMLS CUI [3,1])
C0013216 (UMLS CUI [3,2])
Laboratory test result abnormal
Item
the results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator;
boolean
C0438215 (UMLS CUI [1])
Substance Use Disorders
Item
has history of alcohol or drugs abuse;
boolean
C0038586 (UMLS CUI [1])
Hepatic Metabolism inhibitors
Item
history of use drug inducing and/or inhibitors of hepatic metabolism within 30 days prior to drug study administration;
boolean
C1373178 (UMLS CUI [1,1])
C0243077 (UMLS CUI [1,2])
Monoamine Oxidase Inhibitors
Item
use of mao inhibitors two weeks before the start of treatment; - use of inhibitors of 5-th reuptake,
boolean
C0026457 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnancy or breastfeeding,
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Tobacco use
Item
smoking;
boolean
C0543414 (UMLS CUI [1])
Medication use Regular
Item
use of regular medication within 4 weeks prior to study iniciation;
boolean
C0240320 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
Investigational New Drugs | Study Subject Participation Status
Item
use of experimental drug or participation in any clinical study within 6 months prior to study iniciation.
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Age
Item
age between 18 and 50 years;
boolean
C0001779 (UMLS CUI [1])
Body mass index
Item
body mass index ≥ 18,5 and ≤25,0, can vary up to 15% for the upper limit (18,5 to 28,75);
boolean
C1305855 (UMLS CUI [1])
Good health
Item
good health conditions;
boolean
C3813622 (UMLS CUI [1])
Informed Consent
Item
obtain the informed consent's signed.
boolean
C0021430 (UMLS CUI [1])